Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q9UIQ6

UPID:
LCAP_HUMAN

ALTERNATIVE NAMES:
Insulin-regulated membrane aminopeptidase; Insulin-responsive aminopeptidase; Oxytocinase; Placental leucine aminopeptidase

ALTERNATIVE UPACC:
Q9UIQ6; O00769; Q15145; Q59H76; Q9TNQ2; Q9TNQ3; Q9UIQ7

BACKGROUND:
The enzyme Leucyl-cystinyl aminopeptidase, also referred to as Oxytocinase or Placental leucine aminopeptidase among other names, is integral to the regulation of peptide hormones and neuronal peptides. Its ability to cleave before crucial amino acids such as cysteine and leucine, and its involvement in the degradation of hormones like oxytocin and vasopressin, underscore its significance in maintaining physiological balance. The enzyme's interaction with angiotensin IV hints at its potential role as a receptor in the brain, further highlighting its importance in neurochemical regulation.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of Leucyl-cystinyl aminopeptidase could open doors to potential therapeutic strategies.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.